Try searching for...
Dr Alex Flynn
MBBS (Hons), FRACP, BSc (Adv Maths)
For patients/carers
For doctors
MBBS (Hons), FRACP, BSc (Adv Maths)
Locations
Clinical interests
- Gynaecological cancer
- Colorectal (bowel) cancer
- Gastrointestinal cancer
- Prostate cancer
- Skin cancer
Languages
Fluent
- English
Biography
Clinical interest in gastrointestinal cancers, prostate, melanoma and ovarian cancers
Dr Alex Flynn graduated with honours from the University of Sydney in 2008 and completed medical oncology training at the Calvary Mater Newcastle and the Central Coast Cancer Centre.
She gained clinical trial expertise during her Clinical Trial Fellowship and has been awarded research funding from Tour de Cure, NSWRCRN, AVANT & AGITG for her PhD. She is the primary investigator for the FFTV clinical trial & is involved in the development of international dosing guidelines (ADDIKD).
Alex finds it a privilege to look after patients during what is often the most challenging time of their lives and hopes to bring clear communication and caring to each of her patients.
More information
- Fellowship of the Royal Australian College of Physicians (RACP)
- Australian Gastrointestinal Trials Group (AGITG)
- American Society of Clinical Oncology (ASCO)
- European Society of Clinical Oncology (ESMO)
- Medical Oncology Group of Australia (MOGA)
- Flynn, A., Galettis, P., Gurney, H., Michael, M., Desar, I., Westerdijk, K., ... & Martin, J. (2024). Therapeutic drug monitoring in anticancer agents: perspectives of Australian medical oncologists. Internal Medicine Journal.
- Martin, J. H., Galettis, P., Flynn, A., & Schneider, J. (2024). Phenotype versus genotype to optimize cancer dosing in the clinical setting—focus on 5‐fluorouracil and tyrosine kinase inhibitors. Pharmacology research & perspectives, 12(2), e1182.
